CELLector

CELLector prioritizes cancer cell lines based on patient tumor genomics to align in vitro models with clinically relevant primary tumor subtypes.

Key Features:

• Patient-Genomic-Guided Selection: Uses tumor genomic profiles to guide the selection of cancer cell lines that reflect patient-derived genomic alterations.
• Identification of Recurrent Subtypes: Detects recurrent tumor subtypes and their associated genomic signatures across patient cohorts.
• Prioritization of Cancer Cell Lines: Compares identified genomic signatures to available cancer cell lines to rank lines for inclusion or exclusion in studies.
• Bridging In Vitro and Primary Tumor Outcomes: Maps cell line screen outcomes to precisely defined sub-cohorts of primary tumors to support translational interpretation.
• Development of Prognostic and Therapeutic Markers: Enables discovery and prioritization of patient-derived multivariate prognostic and therapeutic markers using matched genomic signatures and cell-line data.

Scientific Applications:

• Retrospective representativeness analysis: Assess the representativeness of existing cell lines for specific patient tumor subtypes using tumor genomic data.
• Design and prioritization of in vitro studies: Inform selection and prioritization of cell lines for preclinical screens to enhance translational relevance.
• Discovery and prioritization of prognostic and therapeutic markers: Support identification of multivariate markers derived from patient genomics and validated across cell-line models.

Methodology:

Implemented as an R package, CELLector leverages tumor genomics to systematically identify recurrent subtypes and their genomic signatures and evaluates these signatures against available cancer cell lines.